DXC Technology Co 8-K, filed Oct 7, 2020
DXC Technology Co (DXC)
8-K
2020-10-07
For: 2020-10-01
View Original
Added on
April 07, 2026
About this 8-K
DXC Technology Co filed this 8-K on October 7, 2020, reporting on events of October 1, 2020.
Items reported
- Item 2.01: Completed an acquisition or sale of assets
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________________
FORM 8-K
_____________________________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 1, 2020
______________________________________________________________________________
(Exact name of Registrant as specified in its charter)
______________________________________________________________________________
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
, | |||||
(Address of Principal Executive Offices) | (Zip Code) | ||||
Registrant’s telephone number, including area code: (703 ) 245-9675
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.01 Completion of Acquisition or Disposition of Assets.
On October 1, 2020, DXC Technology Company (the “Company”) completed the previously announced sale (the “Sale”) of its U.S. State and Local Health and Human Services business (the “HHS Business”) to Milano Acquisition Corp. (the “Purchaser”), a Delaware corporation affiliated with Veritas Capital Fund Management, L.L.C., a Delaware limited liability company, pursuant to a Purchase Agreement, dated as of March 9, 2020, by and between the Company and the Purchaser (as amended, the “Purchase Agreement”), for total cash consideration of $5,000,000,000 (including $85,000,000 related to future services to be provided by the Company) subject to customary adjustments (the “Consideration”).
All statements in this Current Report on Form 8-K (including all exhibits attached hereto) that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent the Company’s intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors many of which are outside the Company’s control. These factors could cause actual results to differ materially from such forward-looking statements. For a written description of these factors, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, as updated in subsequent SEC filings including the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020. The Company disclaims any intention or obligation to update these forward-looking statements whether as a result of subsequent event or otherwise, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(b) Pro Forma Financial Information.
Unaudited pro forma consolidated financial information of the Company giving effect to the disposition of the Sale, and the related notes thereto, required by Article 11 of Regulation S-X is attached hereto as Exhibit 99.1.
The unaudited pro forma condensed consolidated financial information does not include indirect costs that (a) have been conveyed with the HHS Business (b) the Company is entitled to reimbursement for in order to provide general and administrative services as part of our transition services agreements with the HHS Business and (c) are other general and administrative costs associated with the HHS business that will be reviewed and targeted for elimination. The vast majority of these indirect costs that have not been included in the pro forma consolidated financial information fall into categories (a) and (b) as outlined above.
(d) Exhibits.
Exhibit No. | Description |
99.1 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
DXC TECHNOLOGY COMPANY | |||
Dated: | October 7, 2020 | By: | /s/ Zafar A. Hasan |
Name: | Zafar A. Hasan | ||
Title: | Vice President and Head of Corporate Legal, Corporate Secretary | ||
Exhibit 99.1
DXC TECHNOLOGY COMPANY
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
On October 1, 2020, DXC Technology Company (“DXC” or the “Company”) completed the previously announced sale (the “Sale”) of its U.S. State and Local Health and Human Services (the “HHS Business”) to Veritas Capital. The Sale was accomplished by the cash purchase of all equity interests and assets attributable to the Medicaid Management Information Systems (“MMIS”) business together with future services to be provided by the Company.
The unaudited pro forma condensed consolidated balance sheet of the Company as of June 30, 2020 is presented as if the Sale occurred on June 30, 2020. The unaudited pro forma condensed consolidated statements of operations for the three months ended June 30, 2020 and for the fiscal year ended March 31, 2020 are presented as if the Sale occurred on April 1, 2019.
The unaudited pro forma condensed consolidated financial statements and the accompanying notes should be read in conjunction with the audited consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in DXC’s Form 10-K for the fiscal year ended March 31, 2020 and the unaudited condensed consolidated financial statements and accompanying notes included in DXC’s Form 10-Q for the three months ended June 30, 2020.
The information presented in the “Historical DXC” column in the unaudited pro forma condensed consolidated financial statements reflects DXC’s historical financial statements for the periods presented and do not reflect any adjustments related to the Sale.
The information presented in the “HHS Business" column was derived from DXC’s audited consolidated financial statements and the related accounting records for the fiscal year ended March 31, 2020 and DXC’s unaudited condensed consolidated financial statements and the related accounting records as of and for the three months ended June 30, 2020.
The “Pro Forma Adjustments” column reflects adjustments to give effect to the Sale.
The unaudited pro forma condensed consolidated financial information does not include indirect costs that (a) have been conveyed with the HHS Business (b) the Company is entitled to reimbursement for in order to provide general and administrative services as part of our transition services agreements with the HHS Business and (c) are other general and administrative costs associated with the HHS business that will be reviewed and targeted for elimination. The vast majority of these indirect costs that have not been included in the pro forma consolidated financial information fall into categories (a) and (b) as outlined above.
The pro forma adjustments represent the Company's current best estimates and may differ from those that will be used to calculate the gain or loss on disposal in DXC’s future filings. The unaudited pro forma condensed consolidated financial statements are provided for illustrative and informational purposes only and are not intended to represent or be indicative of what DXC’s results of operations or financial position would have been had the Sale occurred on the dates indicated. The unaudited pro forma condensed consolidated financial statements also should not be considered representative of DXC’s future results of operations or financial position.
See notes to the unaudited pro forma condensed consolidated financial statements for a more detailed discussion of these transactions.
1
DXC TECHNOLOGY COMPANY
PRO-FORMA CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
JUNE 30, 2020
(in millions) | Historical DXC | HHS Business | A | Pro-Forma Adjustments | Pro-Forma DXC | |||||||||||
ASSETS | ||||||||||||||||
Current assets: | ||||||||||||||||
Cash and cash equivalents | $ | 5,509 | $ | — | $ | 85 | B | $ | 5,594 | |||||||
Receivables, net | 4,271 | (142 | ) | — | 4,129 | |||||||||||
Prepaid expenses and other current assets | 928 | (32 | ) | — | 896 | |||||||||||
Total current assets | 10,708 | (174 | ) | 85 | 10,619 | |||||||||||
Intangible assets, net of accumulated amortization | 5,540 | (1,282 | ) | — | 4,258 | |||||||||||
Operating right-of-use assets, net | 1,602 | (95 | ) | — | 1,507 | |||||||||||
Goodwill | 2,057 | (1,350 | ) | — | 707 | |||||||||||
Deferred income taxes, net | 285 | — | — | 285 | ||||||||||||
Property and equipment, net of accumulated depreciation | 3,503 | (41 | ) | — | 3,462 | |||||||||||
Other assets | 4,199 | (35 | ) | — | 4,164 | |||||||||||
Total Assets | $ | 27,894 | $ | (2,977 | ) | $ | 85 | $ | 25,002 | |||||||
LIABILITIES and EQUITY | ||||||||||||||||
Current liabilities: | ||||||||||||||||
Short-term debt and current maturities of long-term debt | $ | 1,682 | $ | (1 | ) | $ | (772 | ) | C | $ | 909 | |||||
Accounts payable | 1,522 | (103 | ) | — | 1,419 | |||||||||||
Accrued payroll and related costs | 766 | (13 | ) | — | 753 | |||||||||||
Current operating lease liabilities | 488 | (30 | ) | — | 458 | |||||||||||
Accrued expenses and other current liabilities | 2,756 | (53 | ) | 85 | D | 2,788 | ||||||||||
Deferred revenue and advance contract payments | 1,030 | (36 | ) | — | 994 | |||||||||||
Income taxes payable | 81 | (2 | ) | — | 79 | |||||||||||
Total current liabilities | 8,325 | (238 | ) | (687 | ) | 7,400 | ||||||||||
Long-term debt, net of current maturities | 10,334 | (1 | ) | (2,696 | ) | C | 7,637 | |||||||||
Non-current deferred revenue | 733 | (31 | ) | — | 702 | |||||||||||
Non-current operating lease liabilities | 1,208 | (75 | ) | — | 1,133 | |||||||||||
Non-current income tax liabilities and deferred tax liabilities | 1,075 | (267 | ) | (22 | ) | B, D | 786 | |||||||||
Other long-term liabilities | 1,277 | (10 | ) | — | 1,267 | |||||||||||
Total Liabilities | 22,952 | (622 | ) | (3,405 | ) | 18,925 | ||||||||||
Total Equity | 4,942 | (2,355 | ) | 3,490 | E | 6,077 | ||||||||||
Total Liabilities and Equity | $ | 27,894 | $ | (2,977 | ) | $ | 85 | $ | 25,002 | |||||||
See accompanying notes to the unaudited pro forma condensed consolidated financial information
2
DXC TECHNOLOGY COMPANY
PRO-FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
TWELVE MONTHS ENDED MARCH 31, 2020
(in millions) | Historical DXC | HHS Business | A | Pro-Forma Adjustments | Pro-Forma DXC | |||||||||||
Revenues | $ | 19,577 | $ | (1,428 | ) | $ | — | $ | 18,149 | |||||||
Costs of services (excludes depreciation and amortization and restructuring costs) | 14,901 | (879 | ) | — | 14,022 | |||||||||||
Selling, general and administrative (excludes depreciation and amortization and restructuring costs) | 2,050 | (13 | ) | (26 | ) | F | 2,011 | |||||||||
Depreciation and amortization | 1,942 | (175 | ) | — | 1,767 | |||||||||||
Goodwill impairment losses | 6,794 | (2,486 | ) | — | 4,308 | |||||||||||
Restructuring costs | 252 | (3 | ) | — | 249 | |||||||||||
Interest expense | 383 | — | (43 | ) | G | 340 | ||||||||||
Interest income | (165 | ) | — | — | (165 | ) | ||||||||||
Gain on arbitration award | (632 | ) | — | — | (632 | ) | ||||||||||
Other income, net | (720 | ) | (2 | ) | — | (722 | ) | |||||||||
Total costs and expenses | 24,805 | (3,558 | ) | (69 | ) | 21,178 | ||||||||||
Loss before income taxes | (5,228 | ) | 2,130 | 69 | (3,029 | ) | ||||||||||
Income tax expense | 130 | (78 | ) | 18 | H | 70 | ||||||||||
Net (loss) income | (5,358 | ) | 2,208 | 51 | (3,099 | ) | ||||||||||
Less: net income attributable to non-controlling interest, net of tax | 11 | — | — | 11 | ||||||||||||
Net (loss) income attributable to DXC common stockholders | $ | (5,369 | ) | $ | 2,208 | $ | 51 | $ | (3,110 | ) | ||||||
Basic EPS | $ | (20.76 | ) | $ | (12.03 | ) | ||||||||||
Diluted EPS | $ | (20.76 | ) | $ | (12.03 | ) | ||||||||||
Weighted average common shares outstanding for: | ||||||||||||||||
Basic EPS | 258.57 | 258.57 | ||||||||||||||
Diluted EPS | 258.57 | 258.57 | ||||||||||||||
See accompanying notes to the unaudited pro forma condensed consolidated financial information
3
DXC TECHNOLOGY COMPANY
PRO-FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
THREE MONTHS ENDED JUNE 30, 2020
(in millions) | Historical DXC | HHS Business | A | Pro-Forma Adjustments | Pro-Forma DXC | |||||||||||
Revenues | $ | 4,502 | $ | (380 | ) | $ | — | $ | 4,122 | |||||||
Costs of services (excludes depreciation and amortization and restructuring costs) | 3,629 | (247 | ) | — | 3,382 | |||||||||||
Selling, general and administrative (excludes depreciation and amortization and restructuring costs) | 539 | (9 | ) | (52 | ) | F | 478 | |||||||||
Depreciation and amortization | 492 | (46 | ) | — | 446 | |||||||||||
Restructuring costs | 72 | — | — | 72 | ||||||||||||
Interest expense | 106 | — | (9 | ) | G | 97 | ||||||||||
Interest income | (23 | ) | — | — | (23 | ) | ||||||||||
Other income, net | (88 | ) | — | — | (88 | ) | ||||||||||
Total costs and expenses | 4,727 | (302 | ) | (61 | ) | 4,364 | ||||||||||
Loss before income taxes | (225 | ) | (78 | ) | 61 | (242 | ) | |||||||||
Income tax benefit | (26 | ) | (21 | ) | 16 | H | (31 | ) | ||||||||
Net (loss) income | (199 | ) | (57 | ) | 45 | (211 | ) | |||||||||
Less: net income attributable to non-controlling interest, net of tax | 6 | — | — | 6 | ||||||||||||
Net (loss) income attributable to DXC common stockholders | $ | (205 | ) | $ | (57 | ) | $ | 45 | $ | (217 | ) | |||||
Basic EPS | $ | (0.81 | ) | $ | (0.86 | ) | ||||||||||
Diluted EPS | $ | (0.81 | ) | $ | (0.86 | ) | ||||||||||
Weighted average common shares outstanding for: | ||||||||||||||||
Basic EPS | 253.63 | 253.63 | ||||||||||||||
Diluted EPS | 253.63 | 253.63 | ||||||||||||||
See accompanying notes to the unaudited pro forma condensed consolidated financial information
4
DXC TECHNOLOGY COMPANY
NOTES TO THE UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The unaudited pro forma condensed consolidated statement of operations for the three months ended June 30, 2020 and fiscal year ended March 31, 2020 as well as the unaudited pro forma condensed consolidated balance sheet as of June 30, 2020 include the following pro forma adjustments:
(A) | The adjustments remove the assets, liabilities, equity and results of operations of the HHS Business. The adjustments to results of operations include only direct costs and exclude certain allocated general corporate overhead expenses, in the amounts of $136 million and $32 million for the fiscal year ended March 31, 2020 and the three months ended June 30, 2020, respectively. |
(B) | Represents the following: |
i. | estimated cash proceeds from the Sale, totaling $5,000 million including $85 million for future services to be provided by the Company, excluding any impact of closing adjustments as defined in the sale and purchase agreement; |
ii. | less estimated transaction costs of $49 million; |
iii. | less estimated tax liability assumed to be paid in cash of $1,123 million; and |
iv. | less cash used to pay short-term debt, long-term debt, and other closing obligations of $3,743 million. |
See footnote C for further discussion of the Company’s use of proceeds.
(C) Represents the Company's use of net cash proceeds from the Sale to pay down existing short-term debt and long-term debt. Cash proceeds from the Sale exclude any impact of closing adjustments as defined in the sale and purchase agreement. See footnote B for further discussion on the Company’s net cash proceeds.
(D) Represents the liability and associated tax impact related to future services to be provided by the Company, as defined in the sale and purchase agreement.
(E) Retained earnings was adjusted as a result of the pro forma adjustments and includes the gain on Sale.
(F) Represents the elimination of transaction costs directly attributable to the Sale.
(G) Represents the impact on interest expense as a result of the use of net proceeds from the Sale to repay short-term debt and long-term debt.
(H) Represents the tax impact of pro forma adjustments. Federal income taxes have not been historically allocated to the HHS Business as they were recorded by DXC. The pro forma adjustments were tax effected using an estimated statutory tax rate of 25.86% in 2020 and 25.86% for the three months ended June 30, 2020 applied to income before income taxes for HHS Business plus the other pro forma adjustments.
5